BGIM
CHRS icon

Brandywine Global Investment Management’s Coherus Oncology CHRS Stock Holding History

Brandywine Global Investment Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-490,545
Closed -$461K – 585
2024
Q3 		$461K Sell
490,545
-209,100
-30% -$287K ﹤0.01% 633
2024
Q2 		$1.21M Buy
699,645
+143,700
+26% +$289K 0.01% 616
2024
Q1 		$1.33M Hold
555,945
– – 0.01% 607
2023
Q4 		$1.85M Sell
555,945
-110,300
-17% -$295K 0.01% 577
2023
Q3 		$2.49M Buy
666,245
+261,800
+65% +$1.21M 0.02% 514
2023
Q2 		$1.73M Buy
404,445
+354,100
+703% +$2.09M 0.01% 567
2023
Q1 		$344K Hold
50,345
– – ﹤0.01% 674
2022
Q4 		$399K Hold
50,345
– – ﹤0.01% 682
2022
Q3 		$484K Sell
50,345
-1,855
-4% -$18.8K ﹤0.01% 679
2022
Q2 		$378K Sell
52,200
-7,800
-13% -$67.8K ﹤0.01% 673
2022
Q1 		$775K Hold
60,000
– – 0.01% 637
2021
Q4 		$958K Sell
60,000
-15,106
-20% -$264K 0.01% 583
2021
Q3 		$1.21M Sell
75,106
-713
-0.9% -$10.5K 0.01% 566
2021
Q2 		$1.05M Buy
+75,819
New +$1.07M 0.01% 572
2021
Q1 		– Sell
-360,344
Closed -$6.26M – 677
2020
Q4 		$6.26M Buy
360,344
+51,120
+17% +$910K 0.05% 340
2020
Q3 		$5.67M Buy
309,224
+156,289
+102% +$2.91M 0.06% 300
2020
Q2 		$2.73M Buy
+152,935
New +$2.59M 0.03% 418

Other funds holding CHRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Brandywine Global Investment Management's CHRS Position: Q4 2024 in Review

Brandywine Global Investment Management sold out of Coherus Oncology (CHRS) in Q4 2024, closing a stake of 490,545 shares — an estimated $461K sold.

Brandywine Global Investment Management first reported a position in CHRS in Q2 2020 and held it in 17 quarters. The position peaked at $6.26M in Q4 2020. 124 funds tracked by Wall St. Rank hold CHRS as of Q4 2024.

  • Brandywine Global Investment Management reported no remaining Coherus Oncology position as of Q4 2024 after selling out during the quarter.
  • Brandywine Global Investment Management sold 490,545 Coherus Oncology shares in Q4 2024, an estimated $461K.
  • Brandywine Global Investment Management first reported a position in Coherus Oncology in Q2 2020 and held it in 17 quarters.
  • Brandywine Global Investment Management's Coherus Oncology position peaked at $6.26M in Q4 2020.
  • 124 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2024.

Based on Brandywine Global Investment Management's 13F filing for Q4 2024, filed 12 Feb 2025.